Treatment Naïve, Chronic HCV and HIV

Peginterferon alfa-2b + RBV versus Interferon alfa-2b

RIBAVIC STUDY

Peginterferon + RBV versus Interferon + RBV in HCV & HIV
RIBAVIC Study: Design

• **Study**
  - Randomized, phase 3, open-label, parallel group trial
  - Conducted at 71 French centers

• **Subjects**
  - N = 412 chronically infected with both HCV and HIV
  - Treatment naïve; 48% genotype 1
  - CD4 >200 cells/mm³

• **Regimens (48 Week Treatment)**
  - Peginterferon alfa-2b 1.5 µg 1x/week + Ribavirin 800 mg/day
  - Interferon alfa-2b: 3 million IU 3x/week + Ribavirin 800 mg/day

• **Primary Endpoint**
  - Undetectable serum HCV RNA 24 weeks after stopping treatment

Peginterferon + RBV versus Interferon + RBV in HCV & HIV.

**RIBAVIC Study: Design**

<table>
<thead>
<tr>
<th>Week</th>
<th>0</th>
<th>48</th>
<th>72</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>205</td>
<td>Peginterferon alfa-2b + Ribavirin</td>
<td>SVR24</td>
</tr>
<tr>
<td>N</td>
<td>207</td>
<td>Interferon alfa-2b + Ribavirin</td>
<td>SVR24</td>
</tr>
</tbody>
</table>

**Drug Dosing**
- Peginterferon alfa-2b: 1.5 μg/kg 1x/week
- Standard Interferon alfa-2b: 3 million units 3x/week
- Ribavirin (divided bid): 800 mg/day

Peginterferon + RBV versus Interferon + RBV in HCV & HIV

RIBAVIC Study: Design

RIBAVIC Study: SVR24 by Treatment Regimen and Genotype

**Conclusion:** “In combination with ribavirin, treatment with peginterferon alfa-2b is more effective than standard interferon alfa-2b for HCV infection in HIV-infected patients.”
This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

**Hepatitis C Online**

[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

**Hepatitis Web Study**


Funded by a grant from the Centers for Disease Control and Prevention.